Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts

Anticancer Research

Volumn 28, Issue 3 A, 2008, Pages 1593-1602

  Sakurai, Yoichi ^a   Yoshida, Ikuo ^a   Kamoshida, Shingo ^a   Inaba, Kazuki ^a   Isogaki, Jun ^a   Komori, Yoshiyuki ^a   Uyama, Ichiro ^a   Tsutsumi, Yutaka ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5' deoxy 5 fluorouridine; Apoptosis; Gastric cancer; Nude mice; Paclitaxel; Thymidine phosphorylase

Indexed keywords

CYTOKERATIN 18; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXIFLURIDINE; MESSENGER RNA; PACLITAXEL; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; DIHYDROURACIL DEHYDROGENASE (NADP); FLOXURIDINE; GENE EXPRESSION; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PACLITAXEL; RNA, MESSENGER; STOMACH NEOPLASMS; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 45949105320     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Macdonald JS and Gohmann JJ: Chemotherapy of advanced gastric cancer: present status, future prospects. Semin Oncol 15: 42-49, 1988.
2. Spears CP, Gustavsson BG, Berne M, Frosing R, Bernstein L and Hayes AA: Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res 48: 5894-5900, 1988.
3. Diasio RB, Beavers TL and Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81: 47-51, 1988.
4. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F and Milano G: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663-1670, 1995.
5. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
6. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N and Ishitsuka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58: 685-690, 1998.
7. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F and Ishitsuka H: Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55: 1091-1097, 1998.
8. Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y and Ishitsuka H: Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull (Tokyo) 31: 175-178, 1983.
9. Ishikawa T, Ura M, Yamamoto T, Tanaka Y and Ishitsuka H: Selective inhibition of spontaneous pulmonary metastasis of Lewis lung carcinoma by 5'-deoxy-5-fluorouridine. Int J Cancer 61:516-521,1995.
10. Nio Y, Kimura H, Tsubono M, Tseng CC, Kawabata K, Masai Y, Hayashi H, Meyer C, Fukumoto M and Tobe T: Antitumor activity of 5'-deoxy-5-fluorouridine in human digestive organ cancer xenografts and pyrimidine nucleoside phosphorylase activity in normal and neoplastic tissues from human digestive organs. Anticancer Res 12: 1141-1146, 1992.
11. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F and Aikou T: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88: 1110-1117, 1996.
12. Fukushima M, Okabe H, Takechi T, Ichikawa W and Hirayama R: Induction of thymidine phosphorylase by interferon and taxanes occurs only in human cancer cells with low thymidine phosphorylase activity. Cancer Lett 187: 103-110, 2002.
13. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y and Ishitsuka H: X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5: 2948-2953, 1999.
14. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N and Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602-2606, 1996.
15. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L and Bokemeyer C: A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 83: 458-462, 2003.
16. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T and Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019, 1998.
17. Motoyama T, Hojo H and Watanabe H: Comparison of seven cell lines derived from human gastric carcinomas. Acta Pathol Jpn 36: 65-83, 1986.
18. Ochiai A, Yasui W and Tahara E: Growth-promoting effect of gastrin on human gastric carcinoma cell line TMK-1. Jpn J Cancer Res 76: 1064-1071, 1985.
19. Yamada Y, Yoshida T, Hayashi K, Sekiya T, Yokota J, Hirohashi S, Nakatani K, Nakano H, Sugimura T and Terada M: p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. Cancer Res 51: 5800-5805, 1991.
20. Geran RI, Greenberg NH, Schumacher AM and Abott BJ: Protocols for screening chemical agents and natural products against animal tumors and other biological systems. 3rd ed. Cancer Chemother Rep 3: 51-61, 1972.
21. Ovejera AA, Houchens DP and Barker AD: Chemotherapy of human tumor xenografts in genetically athymic mice. Ann Clin Lab Sci 8: 50-56, 1978.
22. Houchens DP, Ovejera AA and Baker A: The therapy of human tumors in athymic (nude) mice. In: Proceedings of the Symposium on the Use of Athymic (Nude) Mice in Cancer Research. Houchens DP, and Ovejera AA (eds.). New York, Stuttgart, Gustav Fisher, pp. 267-280, 2007.
23. Gavrieli Y, Sherman Y and Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501, 1992.
24. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M, Jornvall H and Schutte B: Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187: 567-572, 1999.
25. Fujimoto-Ouchi K, Tanaka Y and Tominaga T: Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5- fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 7: 1079-1086, 2001.
26. Sakurai Y, Uraguchi T, Imazu H, Hasegawa S, Matsubara T, Ochiai M and Funabiki T: Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NU. Gastric Cancer 7: 110-116, 2004.
27. Omura K, Kawakami K, Kanehira E, Nagasato A, Kawashima S, Tawaraya K, Watanabe S; Hirano K, Shirasaka T and Watanabe Y: The number of 5-fluoro-2'-deoxyuridine-5'-monophosphate binding sites and reduced folate pool in human colorectal carcinoma tissues: changes after tegafur and uracil treatment. Cancer Res 55: 3897-3901, 1995.
28. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
29. Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71: 543-546, 1992.
30. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852, 1993.
31. Lee JM and Bernstein A: p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 90: 5742-5746, 1993.
32. Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T: p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993.
33. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
34. Cabanillas F, Pathak S, Grant G, Hagemeister FB, McLaughlin P, Swan F, Rodriguez MA, Trujillo J, Cork A and Butler JJ: Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. Am J Med 87: 167-172, 1989.
35. el Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R and Newcomb EW: p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82: 3452-3459, 1993.
36. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B and Kaye SB: Increased accumulation of p53 protein in cisplatinresistant ovarian cell lines. Int J Cancer 55: 678-684, 1993.
37. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ Jr and O'Connor PM: Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649-1654, 1995.
38. Hawkins DS, Demers GW and Galloway DA: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892-898, 1996.
39. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW and Galloway DA: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2: 72-79, 1996.